Martin Miner
This review discusses the latest evidence for the metabolic investigation of erectile dysfunction as it relates to cardiometabolic risk and visceral adiposity, the key component of metabolic syndrome. The authors illustrate this concept with a clinical example from their own practice, and the metabolic investigation of ED as it relates to the etiology and cardiovascular risk stratification utilizing the latest guidelines of cardiovascular risk released this past year. The authors conclude with the levels of evidence for the use of novel biomarkers in the evaluation of the patient with ED as applied to cardiometabolic risk.